---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289234650.md"
description: "Actuate Therapeutics shares are trading higher after the company announced that elraglusib will be evaluated in the BEACON2 clinical trial to identify and advance treatment approaches for children with relapsed and refractory neuroblastoma."
datetime: "2026-06-09T19:52:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289234650.md)
  - [en](https://longbridge.com/en/news/289234650.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289234650.md)
generator: "portal-rs"
---

# 

Actuate Therapeutics shares are trading higher after the company announced that elraglusib will be evaluated in the BEACON2 clinical trial to identify and advance treatment approaches for children with relapsed and refractory neuroblastoma.

### Related Stocks

- [ACTU.US](https://longbridge.com/en/quote/ACTU.US.md)

## Related News & Research

- [Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma | ACTU Stock News](https://longbridge.com/en/news/289185012.md)
- [Comoto Drives $100,000 Fundraising Effort for Pediatric Brain Tumor Foundation](https://longbridge.com/en/news/298512275.md)
- [Is Novo Nordisk (CPSE:NOVO B) Cheap On New Childhood Obesity Trial Data?](https://longbridge.com/en/news/298732114.md)
- [Aflac commemorates National Childhood Cancer and Sickle Cell Disease Awareness Month | AFL Stock News](https://longbridge.com/en/news/298460776.md)
- [BioMarin submits FDA sNDA to expand Voxzogo use to children with hypochondroplasia](https://longbridge.com/en/news/298463433.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**